|
|
|
| home > white papers > Personalised Medicine - Pharma and Dx Firms Share Wider Horizons - DiagnostikNet-BB |
|
|
 WHITE PAPERS |
|
DiagnostikNet-BB
|
|
Personalised Medicine - Pharma and Dx Firms Share Wider Horizons
|
|
Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Zenith Technologies win Cork Company of the Year
We’re very proud to announce that last Friday we won the Cork Company of the Year Award in the corporate category.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Russia Orange Paper: Summary of Year 2013
Synergy Research Group
Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials.
Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >> |
|
 |
Industry Events |
 |
14th Annual Biomarkers Congress
21-22 February 2019, Manchester Central Convention Complex, UK
Oxford Global is proud to present for the 14th year our
flagship Biomarkers Congress, taking place 21 – 22 February
2019 in Manchester, UK. An updated programme ensures you will benefit
from talks on the latest strategies and technologies impacting growth in
the biomarker industry.
More info >> |
|
|
|
